Oriol Segarra, CEO of Uriach, describes the Spanish OTC company’s recent developments and transformation from a domestic organization to a truly European player.
These are very interesting times for Uriach; the company is celebrating its 180th anniversary, has just won OTC company of the year, and has invested in acquisitions such as the Italian company Laborest in 2015, Theralab in Portugal, and two additional acquisitions this year. Take us through these developments and the logic behind them.
During the crisis, the stakeholders of Uriach were able to make strategic decisions which were fundamental in advancing the company. This included reducing the number of ongoing projects and consolidating our focus to priority areas. One of the main initiatives has been to reduce our portfolio dependency on prescription products, therefore moving towards consumer healthcare. Another important angle for a family company like Uriach was to professionalize the management structure. These details were selected to be the engine of growth for Uriach during these difficult years.
The financial crisis in 2008 pushed the company to broaden its horizons outside of Spain in order to survive
